Mirtazapina Flas Alter (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Flas Alter, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral formulation for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapina Flas Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from competitive pricing, regulatory support, and dedicated technical assistance throughout the procurement process.

Mirtazapine is used primarily in the treatment of depressive disorders, acting on noradrenergic and serotonergic pathways. - Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. - Depressive disorder with anxiety: alleviates both depressive and anxiety symptoms. - Treatment‑resistant depression: may be considered when other antidepressants have not provided adequate response.

Mirtazapine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Sedation or drowsiness: may cause daytime sleepiness, especially at treatment initiation. - Increased appetite and weight gain: patients often experience heightened hunger and gradual weight increase. - Dry mouth: reduced salivation leading to discomfort and potential dental issues.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia: marked reduction in white blood cells requiring immediate medical attention. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions characterized by blistering and detachment. - Suicidal thoughts or behavior: emergence of suicidal ideation, particularly during early weeks of therapy.

When prescribing mirtazapine, several safety considerations should be observed. - Assess hepatic function: evaluate liver disease severity and adjust dosage if needed. - Monitor weight: regular checks are advised due to risk of significant weight gain. - Screen for suicidal ideation: closely observe patients, especially during the first few weeks. - Use caution in elderly: increased sensitivity to sedation and orthostatic hypotension. - Avoid abrupt discontinuation: tapering is recommended to prevent withdrawal symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may precipitate hypertensive crisis. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can raise mirtazapine plasma concentrations. - CNS depressants (e.g., benzodiazepines, alcohol): may enhance sedative effects.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: additive dry‑mouth and constipation. - Other serotonergic drugs (e.g., SSRIs, SNRIs, tramadol): risk of serotonin syndrome. - Warfarin: possible alteration of INR, requiring coagulation monitoring.